Premium
Pharmacological activity of the C‐terminal and N‐terminal domains of secretory leukoprotease inhibitor in vitro
Author(s) -
Masuda Kenichi,
Kamimura Takashi,
Watanabe Kunihito,
Suga Tetsuya,
Kanesaki Masaharu,
Takeuchi Akiko,
Imaizumi Atsushi,
Suzuki Yoji
Publication year - 1995
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1995.tb15892.x
Subject(s) - slpi , chemistry , biochemistry , microbiology and biotechnology , biology , immunology , inflammation
1 In order to characterize the physiological functions of the domain structure of secretory leukoprotease inhibitor (SLPI), the biological capacities of half‐length SLPIs, (Serl‐Pro54)SLPI and (Asn55‐Ala107)SLPI, were investigated and compared with those of full‐length SLPI. 2 The activities of these inhibitors against several serine proteases were determined using synthetic chromogenic substrates. The inhibitory capacity of the C‐terminal domain, (Asn55‐Ala107)SLPI, was as strong as that of full‐length SLPI against human neutrophil elastase (NE), cathepsin G and chymotrypsin. It possessed less trypsin inhibitory activity than intact SLPI. For the N‐terminal domain of SLPI, (Serl‐Pro54)SLPI, no inhibitory activity could be detected against the serine proteases tested in this study. 3 The inhibitory activity of (Asn55‐Ala107)SLPI against the proteolysis of the natural substrates elastin and collagen by NE was comparable with that of full‐SLPI (elastin, IC 50 = 907±31 nM for SLPI, 767±33nM for (Asn55‐Ala107)SLPI; collagen, IC 50 = 862 ± 36 nM for SLPI, 727 ±47 nM for (Asn55‐Ala107)SLPI). 4 The binding affinities of full‐ and half‐length SLPIs for heparin were measured by affinity column chromatography. Full‐length SLPI showed high affinity for heparin while the binding capacities of both half‐length SLPIs were lower. (Concentration of NaCl for elution, 0.45 m for SLPI, 0.24 m for (Serl‐Pro54)SLPI, 0.27 m for (Asn55‐Ala107)SLPI). 5 The effects of full‐SLPI and (Asn55‐Ala107)SLPI on blood coagulation were measured using the activated partial thromboplastin time (APTT). Full‐length SLPI prolonged clotting time dose‐dependently (1.25, 2.5 and 5.0 um), whereas (Asn55‐Ala107)SLPI had no effect even at the highest concentration. 6 In conclusion, the C‐terminal domain of SLPI is a promising candidate for the treatment of inflammatory diseases in which participation of neutrophil proteases has been suggested.